Do two immune-biology scores improve response prediction across urothelial cancer cohorts?
Fixed Teff and stromal features evaluated across public urothelial cancer cohorts, with discrimination, calibration, missingness and transport limits.
Daiki Kumakura
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
Recent writing
標的タンパク質分解薬の投与間隔を、最大分解率だけで決められるか
ER-PROTACの公開データを点検し、作用部位曝露と標的回復の仮定が投与頻度・PD指標の比較をどう変えるかを最小モデルで調べる。実薬へのfitと臨床用量提案は行わない。
Virtual Cellは何を予測できたのか――標的遺伝子と評価指標の落とし穴
標的遺伝子の直接効果と摂動応答の予測を分け、最新研究と合成例からVirtual Cellの評価指標を点検する。